Alkermes plc (ALKS) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Alkermes plc (ALKS) advanced +0.27% to $45.37 as options desks priced 53% call premium vs. 47% put protection around the $44 max-pain magnet. Solid 87% profit margin (14% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.
Alkermes (ALKS) has kicked off a phase 2 trial for ALKS 7290 in adults with major depressive disorder, a development that refocuses attention on the stock’s central nervous system pipeline. Investors have already been pa
DUBLIN, October 30, 2026--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants wi
Alkermes is rated Buy as LUMRYZ momentum, LYBALVI trends, and pipeline progress drive growth despite near-term profit pressure. Click for more on ALKS stock.
Alnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, October 20, 2026--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial res
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALKS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALKS. Explore sector supply chains on /butterfly.
Why ALKS Stock advanced +0.27% Today — RQD Quant Desk Flash. Solid 87% profit margin (14% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.